PepGen Inc., (PEPG): Price and Financial Metrics
PEPG Price/Volume Stats
| Current price | $11.85 | 52-week high | $17.51 |
| Prev. close | $11.50 | 52-week low | $3.72 |
| Day low | $11.08 | Volume | 47,100 |
| Day high | $12.13 | Avg. volume | 118,503 |
| 50-day MA | $13.84 | Dividend yield | N/A |
| 200-day MA | $8.15 | Market Cap | 383.39M |
PEPG Stock Price Chart Interactive Chart >
PepGen Inc., (PEPG) Company Bio
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Latest PEPG News From Around the Web
Below are the latest news stories about PEPGEN INC that investors may wish to consider to help them evaluate PEPG as an investment opportunity.
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)- Safety, transcript splicing correction and clinical outcome measures data at 5 mg/kg PGN-EDODM1 dose level in patients from FREEDOM-DM1 clinical trial expected in 2024 - - Clearance of Clinical Trial Application (CTA) by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) extends enrollment in FREEDOM-DM1 Phase 1 clinical trial to third country - BOSTON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generat |
We Think PepGen (NASDAQ:PEPG) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
PepGen Announces Appointment of Howard Mayer, M.D. to Board of DirectorsBOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Howard Mayer, M.D. to the PepGen Board of Directors, effective November 15, 2023. “We are pleased to welcome Dr. Mayer to the PepGen Board,” said James McArthur, Ph.D., President and CEO of PepGen. “His |
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments- Continuing to open CONNECT1-EDO51 trial sites in Canada - - Opening of FREEDOM-DM1 trial sites underway in the U.S. and Canada - - Ended third quarter 2023 with cash and cash equivalents of $129.5 million; cash runway expected into 2025 - BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseas |
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)– Lifting of FDA hold allows FREEDOM-DM1 study to launch in the U.S. with target dose levels of 5 mg/kg, 10 mg/kg and 20 mg/kg – – Safety, transcript splicing and clinical outcome measures data at 5 mg/kg PGN-EDODM1 dose level in patients from FREEDOM-DM1 clinical study expected in 2024 – – Continue to expect safety, muscle exon skipping and dystrophin data at 5 mg/kg PGN-EDO51 dose level in patients from CONNECT1-EDO51 clinical study in mid-2024 – – Cash runway expected to fund operations into |
PEPG Price Returns
| 1-mo | -20.31% |
| 3-mo | 76.08% |
| 6-mo | 114.29% |
| 1-year | -5.65% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 74.26% |
| 2023 | -49.14% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...